Jason is a founder and the executive chairman and acting CEO of Disarm Therapeutics. He is a partner at Atlas Venture where he focuses on the creation, development, and business strategy of novel therapeutics companies. He is a founder and the chairman, and was previously the founding CEO, of Generation Bio, and currently serves on the boards of Replimune, Gemini Therapeutics, Accent Therapeutics, and Bicycle Therapeutics.

Prior to joining Atlas, Jason was president of Epizyme (NASDAQ: EPZM), where he charted the company’s strategic course from a private, research-stage business into the clinic and through partnerships with Celgene, GSK and others and a successful IPO in 2013. Prior to Epizyme, Jason led business development at Alnylam (NASDAQ: ALNY), where he was a member of the leadership team and responsible for partnerships with Roche, Takeda, GSK, Ionis, and others. Before Alnylam, Jason was a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Mersana Therapeutics (NASDAQ: MRSN).

Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the BIDMC Board of Overseers, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council.

Raul is VP, Head of Biology and co-founder of Disarm Therapeutics. He was previously Co-Head, North America, of the Neurology Disease Area Team (NeuroDAT) at Vertex Pharmaceuticals, where he led a strategic and scientific committee responsible for all early stage Neurology Programs. While at Vertex, he also served as the Multiple Sclerosis Disease Area Expert, and as the research representative on the late development team that prepared the IND submission for VX-210, an experimental drug for spinal cord injury. Experienced in forming and leading teams in drug discovery and target prosecution, he was a major initiator or contributor to discovery projects in disorders of the central nervous system involving axo-glial communication, myelination, glial cell biology, and axonal degeneration and protection.

Raul previously held roles as Director of Neurosciences at AlphaGene, and in neuroscience discovery research at Biogen-Idec and Genetics Institute/Wyeth. Raul earned his PhD in Neurobiology from Harvard University, under the supervision of Gerald Fischbach, followed by a postdoctoral fellowship in the Department of Neurobiology at Harvard Medical School. He has served on ad-hoc NIH review panels for spinal cord trauma and brain cancer research, has several publications and patent applications, and authored a chapter in “Culturing Nerve Cells” (Banker and Goslin, Eds, MIT Press), a standard textbook in the field.

Tom directs Disarm Therapeutic’s translational strategy to advance the company’s pipeline into the clinic. His work in neuroscience spans three decades and includes research and leadership positions at the National Institutes of Health, Cephalon, Pfizer, Biogen and most recently Takeda Pharmaceuticals, where he was responsible for evaluating new technologies and advancing the company’s CNS portfolio through partnerships. Throughout his career, Tom has led teams bringing new therapeutics from discovery through clinical development. He is the author of more than 50 peer-reviewed articles and an inventor on numerous issued and pending patents.

Kimi is the CFO of Sage Therapeutics and has strong operational and finance experience from senior management positions at Millennium, Biogen and emerging life science companies. Prior to joining Sage in 2013, Kimi served as the Chief Operating Officer, North America, for Santhera Pharmaceuticals and held the role of Vice President of Finance at Cyberkinetics Neurotechnology Systems. Previously, Kimi held roles of increasing responsibility at Millennium Pharmaceuticals and Biogen, Inc. She also worked as a business assurance manager at PricewaterhouseCoopers LLP and started her career in chemistry-related positions at various Boston-based companies.

Kimi holds a B.A. in chemistry from Drew University and an M.B.A. from Northeastern University. She earned her CPA in Massachusetts.

Peter is a Professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine and Director of the Johns Hopkins Multiple Sclerosis (MS) Center and the Division of Neuroimmunology and Neuroinfectious Diseases.

Peter earned a BS from Yale College, MD from Brown University, and completed a research fellowship at the National Institutes of Health (NIH). He has been the principal investigator on several clinical trials and also oversees translational laboratory research projects. He is the recipient of a Jacob Javits Neuroscience Investigator award from the NIH. Peter also recently received the Barancik Award for Innovation in MS research.

Scott has worked at Abbott and subsequently AbbVie for more than 20 years. He is currently AbbVie’s Vice President, Scientific Affairs and Head of AbbVie Ventures, where he works closely with the Chief Strategy Officer and executive management team to identify and execute on strategic venture investments that are closely aligned with AbbVie’s overall R&D and corporate strategy. Scott also serves as one of AbbVie’s primary spokespersons for R&D to global media, governmental officials, and institutional investors.

In his previous role, Scott was the head of Pharmaceutical Development at AbbVie, a global scientific and operational organization responsible for advancing a broad portfolio of early and late stage pre-registration pipeline compounds as well as marketed products within oncology, neurology, immunology, renal, infectious disease, and women’s and men’s health therapeutic areas.

Scott earned his bachelor’s degree in biochemistry from the University of Illinois at Urbana-Champaign.  He earned his medical degree from The Johns Hopkins University School of Medicine and completed ophthalmology training at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.

Douglas Kerr, MD, PhD, MBA, is the head of preclinical research and clinical development at Generation Bio. Previously, Doug was responsible for the development of rare disease programs in neurology at Shire.  At Biogen, he was the global lead for a series of programs in Alzheimer’s disease, Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy (SMA), including the team that developed Spinraza, now approved for SMA. Before his career in industry, Dr. Kerr directed a lab at John Hopkins School of Medicine that investigated fundamental aspects of motor neuron and axon biology.

Doug is a neurologist and neuroscientist with over 120 publications in medical journals. He received his MD and PhD degree in Biochemistry and Molecular biology from Jefferson Medical College and his MBA from Princeton.

Todd is the Director of Molecular Discovery and has more than 12 years of industry experience.

Prior to joining Disarm, Todd held positions at Alkermes and Boehringer-Ingelheim. Most recently he led a medicinal chemistry effort that delivered a drug candidate to proceed into clinical trials. He contributed to the molecular discovery and lead optimization of several other development candidates for immunology, inflammation and cardiometabolic indications. He is the author of over 30 patents and peer-reviewed publications.

Todd earned his PhD in organic chemistry at the University of Pittsburgh and was an NIH postdoctoral fellow with Amos B. Smith, III at the University of Pennsylvania.